PowerShares Dynamic Large Cap Growth ETF

Latest PowerShares Dynamic Large Cap Growth ETF News and Updates

  • uploads///ANR
    Consumer

    What Analysts Recommend for Priceline after 3Q17 Results

    Of the 31 analysts rating Priceline’s stock after the company’s 3Q17 earnings report, 19.4% (six analysts) have issued a “strong buy” rating and 58.1% (18 analysts) have issued a “buy” rating.

    By Ally Schmidt
  • uploads///Margins
    Company & Industry Overviews

    Which Off-Price Retailer Is Operating at the Highest Margins?

    Major off-price retailers have strong margins supported by lean operating models, efficient inventory management, and strong vendor relationships.

    By Sirisha Bhogaraju
  • uploads///BG Foods Quarterly Profit Margins
    Earnings Report

    A Close Look at B&G Foods’ Operating Margins in Fiscal 4Q15

    B&G Foods (BGS) reported that operating margin for fiscal 4Q15 rose to 14.2% compared to 12.7% in 4Q14. Operating margin for fiscal 2015 was 17.8% compared to 13.6% in 2014.

    By Sushree Mohanty
  • uploads///Chart  CP
    Company & Industry Overviews

    CP’s Rail Traffic Growth Was the Lowest among Its Peers

    Canadian Pacific Railway (CP) reported 1.5% YoY (year-over-year) total traffic volume growth in Week 49.

    By Anirudha Bhagat
  • uploads///Part  Short interest
    Materials

    What Praxair’s Short Interest Suggests before 4Q17 Earnings

    The latest short interest data as of December 30, 2017, show that Praxair’s (PX) short interest has increased since its 3Q17 earnings were announced on October 26, 2017.

    By Peter Neil
  • uploads///Revenue
    Consumer

    Priceline’s 3Q17 Revenue Defies Tough Conditions

    For the third quarter of 2017, Priceline’s (PCLN) revenue rose 20.2% YoY or year-over-year to $4.4 billion, driven by strong gross bookings growth of 19% YoY.

    By Ally Schmidt
  • uploads///Investment
    Earnings Report

    How the Meituan–Dianping Investment Could Help Priceline

    On October 19, Priceline (PCLN) announced its $450.0 million investment in China-based Meituan–Dianping.

    By Ally Schmidt
  • uploads///EBITDA
    Consumer

    Why Priceline’s Margin Is on a Downtrend

    For 3Q17, Priceline’s management expects its gross profit to increase 15.5%–20.5%.

    By Ally Schmidt
  • uploads///Valuation
    Consumer

    What’s Priced into Marriott’s Valuation Multiple Now?

    Marriott is now trading at a forward EV-to-EBITDA multiple of 15.5x, compared with its average historical valuation of 13.9x since January 2008.

    By Ally Schmidt
  • uploads///Alibaba
    Consumer

    Could Marriott’s Partnership with Alibaba Be a Game Changer?

    Marriott (MAR) has entered into a joint venture agreement with China’s Alibaba Group (BABA) with an aim to provide a seamless travel experience in China.

    By Ally Schmidt
  • uploads///Leverage
    Consumer

    What Should We Make of Priceline’s Increasing Leverage?

    Priceline has been funding some of its acquisitions through debt. Total debt on its balance sheet has risen from $3.9 billion at the end of 2014 to 6.2 billion at the end of 2015.

    By Ally Schmidt
  • uploads///Chart  Oncology
    Earnings Report

    Eli Lilly in 2Q17: Oncology Products Lose Revenues

    Alimta sales fell ~12.0% to $532.9 million in 2Q17 compared to $607.1 million in 2Q16.

    By Mike Benson
  • uploads///Chart  Revenues
    Company & Industry Overviews

    Bristol-Myers Squibb Reported Revenue Growth in 1Q17

    Bristol-Myers Squibb (BMY) reported 12% growth in its top line to ~$4.93 billion during 1Q17 due to 13% operational growth in its revenues

    By Mike Benson
  • uploads///Chart  Endo
    Company & Industry Overviews

    Performance of Eli Lilly’s Endocrine Products in 1Q17

    Humalog reported growth of 17% to $708.4 million during 1Q17, compared to $606.3 million for 1Q16.

    By Mike Benson
  • uploads///Chart  Development
    Earnings Report

    Eli Lilly & Co.’s Developments in 1Q17

    In 1Q17, Eli Lilly and Boehringer Ingelheim launched Synjardy XR tablets in the US for patients with type 2 diabetes.

    By Mike Benson
  • uploads///Chart  Oncology
    Company & Industry Overviews

    Exploring Eli Lilly’s Oncology Franchise in 2016

    Eli Lilly’s (LLY) Human Pharmaceuticals segment also consists of the oncology franchise. Key drugs in this franchise include Alimta, Erbitux, Cyramza, and Portrazza.

    By Mike Benson
  • uploads///Chart
    Company & Industry Overviews

    A Look at Opdivo’s Performance in 2016

    Bristol-Myers Squibb’s (BMY) latest drug, Opdivo, was the seventh drug to be approved by the FDA for the treatment of melanoma.

    By Mike Benson
  • uploads///Chart  Oncology
    Company & Industry Overviews

    Eli Lilly & Co.’s Oncology Franchise

    Erbitux’s sales fell 13% to $153.7 million in 4Q16, compared to ~$176.2 million in 4Q15.

    By Mike Benson
  • uploads///Chart
    Earnings Report

    Bristol-Myers Squibb’s Strong Oncology Segment

    With the strong performance of Opdivo, Bristol-Myers Squibb’s (BMY) oncology segment emerged as its largest revenue contributor in 4Q16.

    By Mike Benson
  • uploads///Chart  Oncology
    Earnings Report

    What to Expect from Eli Lilly’s Oncology Franchise in 4Q16

    The oncology franchise contributes around 18% of Lily’s total revenues.

    By Mike Benson
  • uploads///Chart
    Company & Industry Overviews

    How Did Bristol-Myers Squibb’s Blockbuster Oncology Drug Perform?

    Bristol-Myers Squibb’s (BMY) latest drug Opdivo was the seventh drug to be approved by the US FDA for the treatment of melanoma.

    By Mike Benson
  • uploads///Chart
    Company & Industry Overviews

    How Did Bristol-Myers Squibb’s Oncology Segment Perform in 3Q16?

    Due to the strong performance of Opdivo, the oncology segment has emerged as the largest revenue contributor for Bristol-Myers Squibb (BMY) in 3Q16.

    By Mike Benson
  • uploads///Chart  Oncology
    Company & Industry Overviews

    What You Should Know about Eli Lilly’s Oncology Franchise

    Eli Lilly’s (LLY) Human Pharmaceuticals segment also contains its oncology franchise. Key drugs in this franchise include Alimta, Erbitux, and Cyramza.

    By Mike Benson
  • uploads///Chart
    Earnings Report

    Eli Lilly and Co.’s 3Q16 Estimates: Oncology Franchise

    Oncology franchise Eli Lilly and Co.’s (LLY) human pharmaceuticals segment also consists of the oncology franchise. The oncology franchise contributes around 18% of total revenues for Lilly. Key drugs in this segment include Alimta, Erbitux, and Cyramza. A new drug, Portrazza, launched in US markets in December 2015. Erbitux Erbitux is a drug used in […]

    By Mike Benson
  • uploads///Chart
    Company & Industry Overviews

    Roche Goes Up against Bristol-Myers Squibb in Oncology Drug Space

    Bristol-Myers Squibb’s (BMY) latest drug, Opdivo ,was the seventh drug to be approved by the FDA for the treatment of melanoma. Opdivo reported revenues of $840 million in 2Q16, as compared to $122 million in 2Q15.

    By Mike Benson
  • uploads///Chart  Neuro
    Company & Industry Overviews

    Eli Lilly’s Antidepressant and Schizophrenia Drug Sales Are Down

    Another franchise from Eli Lilly’s Human Pharmaceuticals segment is the neuroscience franchise—its drugs include Zyprexa, Cymbalta, and Strattera.

    By Mike Benson
  • uploads///prces
    Consumer

    How Will Dollar General’s Stock Price Respond to the Fiscal 2Q16 Results?

    Dollar General’s stock price has risen by 23.6% on a YTD basis to $89.49 as of August 16, 2016.

    By Amanda Lawrence
  • uploads///revenues by geography
    Company & Industry Overviews

    Understanding Intuitive Surgical’s Geographical Profile

    Intuitive Surgical (ISRG) has established geographical growth as one its major growth drivers after procedure growth.

    By Sarah Collins
  • uploads///Q Makeup overview
    Company & Industry Overviews

    Estée Lauder’s Makeup Segment Boosted Its Operating Income

    Estée Lauder’s makeup segment’s net revenue rose 7.3% in reported terms and 11% in constant currency terms to $1.2 billion in fiscal 3Q16.

    By Penny Morgan
  • uploads///TJX pie chart
    Earnings Report

    TJX Companies’ US Business in Fiscal 4Q16

    The US business of TJX Companies consists of 1,156 T.J. Maxx stores, 1,007 Marshalls stores, 526 HomeGoods stores, and eight Sierra Trading Post stores.

    By Sirisha Bhogaraju
  • uploads///hrl pm
    Company & Industry Overviews

    Credit Agricole Downgrades Hormel Foods to ‘Underperform’

    Hormel Foods Corporation (HRL) has a market cap of $22.7 billion. HRL fell by 3.6% to close at $42.89 per share as of February 18, 2016.

    By Gabriel Kane
  • uploads///GDP
    Earnings Report

    Carnival Sees China as Its Biggest Potential Area of Expansion

    Carnival identified China as its biggest potential area of expansion. It announced that Carnival Cruise Line will enter the Chinese market in 2017.

    By Ally Schmidt
  • uploads///Revs distri for DIS in FY
    Earnings Report

    Assessing Disney’s Business Segment Performance in Fiscal 2015

    Disney’s (DIS) Media Networks segment was the biggest contributor to its revenue, at 44% or $52.5 billion, in fiscal 2015.

    By Shirley Pelts
  • uploads///part  power sector
    Company & Industry Overviews

    Understanding the structure of the global power sector

    While the power sector differs country by country, the operational structure of the sector across the world is pretty much the same.

    By Mike Sonnenberg
  • Market Realist Logo

    © Copyright 2022 Market Realist. Market Realist is a registered trademark. All Rights Reserved. People may receive compensation for some links to products and services on this website. Offers may be subject to change without notice.